Purple (PRPL) Q2 2026 Earnings Call Transcript

Purple (PRPL) reported Q2 wholesale revenues down about 19% year over year, citing mattress-category softness. The company said it invested over $4 million incrementally in marketing with retail partners, which affected reported wholesale revenue; excluding it, wholesale revenue would have declined about 8%. Purple also cited higher gross margins and profitability above last year, plus a June pricing action. NASDAQ confirmed PRPL regained minimum bid compliance after a July reverse split.

Original reporting
Published Aug 18, 2026, 12:15 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 18, 2026, 12:17 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Purple (PRPL) Q2 2026 Earnings Call Transcript — source image
Decision brief

The 30-second read

$PRPLNeutralMed
01

Why it matters

Traders can reassess near-term channel health by separating reported wholesale revenue from the incremental marketing impact, while also adjusting for the GAAP gross margin presentation change.

02

Market read

The call transcript centers on wholesale weakness versus margin resilience, plus execution updates across e-commerce, premium mix, and retail showroom expansion.

03

What to watch

The excerpt highlights a cost reclassification that boosts GAAP gross margin by 505 bps, which can make profitability look better even if operating cash generation is unchanged.

Relevance 6/10Novelty 5/10Timing: during/after the Q2 2026 earnings call transcript (pre-market context not specified)

Background

Purple discusses Q2 wholesale performance, marketing investment with retail partners, e-commerce improvements, premium product mix, distribution expansion, and financial discipline.

Company-level read

Ticker impact

$PRPLNeutralMedium confidence
Context

Purple reports Q2 wholesale revenue down about 19% YoY, with incremental marketing spend affecting reported results and margins improving despite lower sales.

Expected impact

Likely choppy-to-negative near term if investors focus on the 19% wholesale decline, but less negative if they credit margin resilience and channel execution.

Evidence & confidence

The transcript provides directional performance (wholesale down, margins up) and a specific accounting reclassification, but it does not include fresh guidance or quantified full-year targets in the provided excerpt.

Market effects

Signals ongoing demand pressure in the broader mattress category while premium positioning (Rejuvenate) and retail showroom expansion remain key differentiators.

No specific regional impact disclosed in the excerpt.

No explicit global macro or international demand drivers mentioned.

Counterpoint

Investors may underweight the wholesale decline because management frames it as partly driven by deliberate marketing investment and customer-payment timing, not purely underlying demand deterioration.

Key entities

  • Purple

    Reports Q2 wholesale revenue down ~19% YoY, incremental marketing investment, margin improvement, and distribution execution including showroom openings and Purple Royale rollout.

Related articles

$PRPLMed

Purple Innovation Reports Third Quarter 2026 Results

Purple Innovation, Inc. (PRPL) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 CONFIDENTIAL DRAFT Purple Innovation Reports Third Quarter 2026 Results Positive Operating Cash Flow for the Third Consecutive Quarter Preparing for Major Mattress Portfolio Refresh to Strengthen Performance in 2027 Lehi, Utah, November 4, 2026 – Purple Innovation, I

$PRPLMedAI 8/10

Why Purple (PRPL) Stock Is Trading Lower Today

Purple (PRPL) shares fell 24.6% after the company reported Q2 revenue of $98.27 million, down 6.5% year over year and below Wall Street expectations. Adjusted EPS was a loss of $1.52, better than forecast. Purple kept full-year revenue guidance around $430 million, but investors focused on the quarterly sales miss.

$PRPLMed

Purple Innovation Reports Second Quarter 2026 Results

Purple Innovation, Inc. (PRPL) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Purple Innovation Reports Second Quarter 2026 Results Showroom Revenue Up 16.6% and Comparable Revenue Up 18% GAAP Net Loss of $3.2 Million in the Second Quarter Adjusted EBITDA Improves $4.4 Million to $2.1 Million Regains Compliance with Nasdaq Minimum Bid Price Re

$PRPLMedAI 8/10

Purple (NASDAQ:PRPL) Misses Q2 CY2026 Sales Expectations

Purple (NASDAQ:PRPL) reported Q2 CY2026 revenue of $98.27 million, down 6.5% year on year, missing market expectations. Non-GAAP adjusted EPS was -$1.52, better than analysts’ consensus. For next quarter, management guided revenue to $430 million at the midpoint. The article also notes negative operating margin and ongoing revenue decline.

Med

TELUS (TU) Q3 2026 Earnings Call Transcript

TELUS (TU) outlined three key priorities during its Q3 2026 earnings call: strengthening its financial foundation, honing operational discipline, and deploying resources for growth. The company aims to reduce debt, achieve a net debt to adjusted EBITDA leverage ratio of 3x or lower by 2028, and target $900 million in annualized cash savings by 2028. TELUS plans to monetize non-core assets, streamline operations, and invest in its PureFibre network for growth in AI infrastructure.

$PAHCMedAI 8/10

Phibro Animal (PAHC) Q1 2027 Earnings Call Transcript

Phibro Animal Health (PAHC) reported Q1 2027 sales growth of 6% to $386.8M and adjusted EBITDA growth of 4% to $64.3M. Performance Products and Mineral Nutrition segments drove growth, while Animal Health saw a 3% increase. The company maintained its full-year guidance and expects protein demand to grow, despite near-term pressure on producer profitability.